Hayleigh Collins | executive |
Sean Nolan | executive |
Sukumar Nagendran | executive |
Kamran Alam | executive |
Kristen Kluska | analyst |
Christopher Raymond | analyst |
Whitney Ijem | analyst |
Salveen Richter | analyst |
Gil Blum | analyst |
Maurice Raycroft | analyst |
Jack Allen | analyst |
Joon Lee | analyst |
Silvan Tuerkcan | analyst |
Keith R. Tapper | analyst |
Greetings, and welcome to the Taysha Gene Therapies' Third Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Hayleigh Collins, the Director and Head of Investor Relations. Thank you, and you may proceed, Hayleigh.
Thank you. Good afternoon, and welcome to Taysha's Third Quarter 2024 Financial Results and Corporate Update Conference Call.